When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key ...

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called homologous recombination, the cell uses loops in its ...

The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

Scientists remain divided over whether the human Y chromosome will eventually vanish. But clinicians say the real concern ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called ...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient ...

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...

The agency said that although Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.